185 related articles for article (PubMed ID: 37756582)
1. Polymorphisms in Cyclooxygenase, Lipoxygenase, and TP53 Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial.
Davies JR; Mell T; Fuller H; Harland M; Saleh RNM; Race AD; Rees CJ; Brown LC; Loadman PM; Downing A; Minihane AM; Williams EA; Hull MA
Cancer Prev Res (Phila); 2023 Nov; 16(11):621-629. PubMed ID: 37756582
[TBL] [Abstract][Full Text] [Related]
2. The effect of aspirin and eicosapentaenoic acid on urinary biomarkers of prostaglandin E
Sun G; Fuller H; Fenton H; Race AD; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
Int J Cancer; 2024 Mar; 154(5):873-885. PubMed ID: 37855394
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
Trials; 2013 Jul; 14():237. PubMed ID: 23895505
[TBL] [Abstract][Full Text] [Related]
5. Colorectal polyp outcomes after participation in the seAFOod polyp prevention trial: Evidence of rebound elevated colorectal polyp risk after short-term aspirin use.
Downing A; Fenton H; Nickerson C; Loadman PM; Williams EA; Rees CJ; Brown LC; Morris EJA; Hull MA
Aliment Pharmacol Ther; 2023 Sep; 58(6):562-572. PubMed ID: 37518954
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps.
Ulrich CM; Bigler J; Sparks R; Whitton J; Sibert JG; Goode EL; Yasui Y; Potter JD
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):889-93. PubMed ID: 15159324
[TBL] [Abstract][Full Text] [Related]
7. Colorectal polyp prevention by daily aspirin use is abrogated among active smokers.
Drew DA; Goh G; Mo A; Grady JJ; Forouhar F; Egan G; Swede H; Rosenberg DW; Stevens RG; Devers TJ
Cancer Causes Control; 2016 Jan; 27(1):93-103. PubMed ID: 26510933
[TBL] [Abstract][Full Text] [Related]
8. Plasma and rectal mucosal oxylipin levels during aspirin and eicosapentaenoic acid treatment in the seAFOod polyp prevention trial.
Fuller H; Race AD; Fenton H; Burke L; Downing A; Williams EA; Rees CJ; Brown LC; Loadman PM; Hull MA
Prostaglandins Leukot Essent Fatty Acids; 2023 May; 192():102570. PubMed ID: 37003144
[TBL] [Abstract][Full Text] [Related]
9. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.
Barry EL; Sansbury LB; Grau MV; Ali IU; Tsang S; Munroe DJ; Ahnen DJ; Sandler RS; Saibil F; Gui J; Bresalier RS; McKeown-Eyssen GE; Burke C; Baron JA
Cancer Epidemiol Biomarkers Prev; 2009 Oct; 18(10):2726-33. PubMed ID: 19755647
[TBL] [Abstract][Full Text] [Related]
11. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.
Nan H; Hutter CM; Lin Y; Jacobs EJ; Ulrich CM; White E; Baron JA; Berndt SI; Brenner H; Butterbach K; Caan BJ; Campbell PT; Carlson CS; Casey G; Chang-Claude J; Chanock SJ; Cotterchio M; Duggan D; Figueiredo JC; Fuchs CS; Giovannucci EL; Gong J; Haile RW; Harrison TA; Hayes RB; Hoffmeister M; Hopper JL; Hudson TJ; Jenkins MA; Jiao S; Lindor NM; Lemire M; Le Marchand L; Newcomb PA; Ogino S; Pflugeisen BM; Potter JD; Qu C; Rosse SA; Rudolph A; Schoen RE; Schumacher FR; Seminara D; Slattery ML; Thibodeau SN; Thomas F; Thornquist M; Warnick GS; Zanke BW; Gauderman WJ; Peters U; Hsu L; Chan AT; ;
JAMA; 2015 Mar; 313(11):1133-42. PubMed ID: 25781442
[TBL] [Abstract][Full Text] [Related]
12. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
13. Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.
Kleinstein SE; Heath L; Makar KW; Poole EM; Seufert BL; Slattery ML; Xiao L; Duggan DJ; Hsu L; Curtin K; Koepl L; Muehling J; Taverna D; Caan BJ; Carlson CS; Potter JD; Ulrich CM
Genes Chromosomes Cancer; 2013 May; 52(5):437-49. PubMed ID: 23404351
[TBL] [Abstract][Full Text] [Related]
14. Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps.
Poole EM; Bigler J; Whitton J; Sibert JG; Potter JD; Ulrich CM
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):502-8. PubMed ID: 16537708
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib use and circulating oxylipins in a colon polyp prevention trial.
Martinez JA; Yang J; Wertheim BC; Roe DJ; Schriewer A; Lance P; Alberts DS; Hammock BD; Thompson PA
PLoS One; 2018; 13(4):e0196398. PubMed ID: 29698447
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial.
Hubner RA; Muir KR; Liu JF; Logan RFA; Grainge MJ; Houlston RS;
Int J Cancer; 2007 Nov; 121(9):2001-2004. PubMed ID: 17640058
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the polyp prevention trial.
Sansbury LB; Bergen AW; Wanke KL; Yu B; Caporaso NE; Chatterjee N; Ratnasinghe L; Schatzkin A; Lehman TA; Kalidindi A; Modali R; Lanza E
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):494-501. PubMed ID: 16537707
[TBL] [Abstract][Full Text] [Related]
18. Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention.
Barry EL; Mott LA; Sandler RS; Ahnen DJ; Baron JA
Cancer Prev Res (Phila); 2011 Dec; 4(12):2072-82. PubMed ID: 21930798
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial.
Johnson CC; Hayes RB; Schoen RE; Gunter MJ; Huang WY;
Am J Gastroenterol; 2010 Dec; 105(12):2646-55. PubMed ID: 20808298
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
